Universal Electronics Inc. to Provide Voice-Enabled Remotes for Liberty Global’s New Environmentally Friendly Set-Top Box
7.10.2020 22:10:00 EEST | Business Wire | Press release
Universal Electronics Inc. (UEI), the global leader in universal control and sensing technologies for the smart home, has been selected to provide voice-enabled remote control units to Liberty Global, one of the world’s leading converged video, broadband and communication companies with 11 million customers in six European countries, for its new environmentally friendly set-top box.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005930/en/
Universal Electronics Inc. to Provide Voice-Enabled Remotes for Liberty Global’s New Environmentally Friendly Set-Top Box (Photo: Business Wire)
The BLE voice-enabled remote control is powered by UEI chip technology, which enables longer battery life, with automated setup and control through UEI’s QuickSet® platform, which provides an unmatched cloud-based solution for simplifying universal entertainment and smart home control.
The remote is designed to improve the customer experience by using voice recognition technology to search for content on Liberty Global’s RDK-based Horizon 4 platform which offers access to live TV, on-demand content and OTT apps.
In August 2020, Liberty Global introduced the compact 4K Mini TV Box, which is made from 35% recycled plastic and reduces energy consumption by 77% compared to its previous set-top boxes. The 4K Mini TV Box, the company’s first all-IP device, is powered by Liberty Global’s next generation TV platform, Horizon 4.
The 4K Mini TV Box is currently available for customers of Liberty’s UPC Poland, the country’s largest cable provider. The set-top box will be introduced in Liberty Global’s other markets in 2021.
“We have a solid and collaborative relationship with UEI with a shared commitment to quality and sustainability,” said Pieter Vervoort, Vice President, Entertainment Products at Liberty Global.
UEI has implemented several sustainability initiatives in its development, supply chain and manufacturing processes, including remanufacturing remote controls, using recycled materials and developing more energy efficient products.
“We are pleased and proud to be selected for this project as it allows us to be at our best, providing an extremely easy-to-use control solution in a durable, sustainable way,” said Menno Koopmans, UEI’s Senior Vice President of Global Sales and Marketing. “Building upon our long-term partnership, we are thrilled to deliver another piece of cutting-edge, voice-enabled control technology to Liberty Global.”
UEI has been at the forefront of developing entertainment and smart home control technologies for over three decades. UEI was the first to introduce voice control and advanced features such as automated setup and universal control of connected devices through its QuickSet platform. Since 2015, UEI has shipped over 100 million of its voice-enabled remote controls to customers around the world.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, please visit www.uei.com.
All trademarks appearing herein are the property of their respective owners.
QuickSet is a trademark of Universal Electronics Inc.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release including the BLE voice enabled remote control, and UEI’s proprietary chip and QuickSet technologies; the continued penetration and growth of the Liberty Global Horizon 4 platform and 4K Mini TV Box, and other products and consumer technologies identified in this release; and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005930/en/
Contact information
Shoshana Leon
Corporate Communications
Universal Electronics Inc.
sleon@uei.com
+1 480-521-3354
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom